BGI Genomics Co., Ltd. provides genomic sequencing and proteomic services in China and internationally. The company offers solutions to various applications, such as basic research covering human, plant, animal, and microbial species; clinical research in human health; genetic testing and screening; drug discovery and development; and agriculture and biodiversity preservation and sustainability. It provides DNA, RNA, and customized sequencing solutions; and mass spec services, as well as COVID-19 PCR test kits and COVID lab solutions. In addition, the company offers diagnostics and precision medicines for COVID-19, infectious diseases, and oncology. It serves academic institutions, pharmaceutical companies, health care providers, and other organizations. The company was formerly known as Shenzhen BGI Medicine Co., Ltd. and changed its name to BGI Genomics Co., Ltd. in 2015. BGI Genomics Co., Ltd. was founded in 1999 and is headquartered in Shenzhen, China. BGI Genomics Co., Ltd operates as a subsidiary of BGI Group.
Metrics to compare | 300676 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship300676PeersSector | |
---|---|---|---|---|
P/E Ratio | −19.8x | −6.3x | −0.5x | |
PEG Ratio | 0.01 | 0.22 | 0.00 | |
Price/Book | 2.1x | 3.4x | 2.6x | |
Price / LTM Sales | 5.2x | 10.0x | 3.1x | |
Upside (Analyst Target) | 4.4% | 29.1% | 48.3% | |
Fair Value Upside | Unlock | −5.0% | 7.6% | Unlock |